APVO Aptevo Therapeutics Inc.

$2.94

Aptevo Therapeutics Inc. (APVO) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $5.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.5% since its last earnings release on August 14, 2026.

Aptevo Therapeutics Beat Consensus Estimates
Friday, August 14, 2026 · 8:05 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · Before Open
Earnings Whisper
-
vs ($5.67)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.

Sector

Healthcare

Industry

Biotechnology